TIROFIBAN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tirofiban Hydrochloride, and when can generic versions of Tirofiban Hydrochloride launch?
Tirofiban Hydrochloride is a drug marketed by Eugia Pharma, Gland Pharma Ltd, and Nexus. and is included in three NDAs.
The generic ingredient in TIROFIBAN HYDROCHLORIDE is tirofiban hydrochloride. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tirofiban hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tirofiban Hydrochloride
A generic version of TIROFIBAN HYDROCHLORIDE was approved as tirofiban hydrochloride by GLAND PHARMA LTD on April 8th, 2021.
Summary for TIROFIBAN HYDROCHLORIDE
Recent Clinical Trials for TIROFIBAN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Lu Hua | Phase 4 |
CSPC Pharmaceutical Group Limited | Phase 4 |
Second Affiliated Hospital of Guangxi Medical University | Phase 4 |
Pharmacology for TIROFIBAN HYDROCHLORIDE
Drug Class | Platelet Aggregation Inhibitor |
Physiological Effect | Decreased Platelet Aggregation |
Anatomical Therapeutic Chemical (ATC) Classes for TIROFIBAN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for TIROFIBAN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AGGRASTAT | Injection | tirofiban hydrochloride | 5 mg/100 mL | 020913 | 1 | 2019-08-29 |
AGGRASTAT | Injection | tirofiban hydrochloride | 12.5 mg/250 mL | 020913 | 1 | 2018-10-03 |